Contineum Therapeutics

top of page

RBC Global Healthcare Conference: With clinical validation that has been seen on the target from a large pharma, Contineum has moved its LPA1R antagonist aggressively into the clinic for IPF

CEO Carmine Stengone describes the target, and why he believes Contineum has a best-in-class asset. Plus, background on a key upcoming readout for the company's M1R antagonist that partner JNJ will have in major depressive disorder later this year.

Company News

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

RBC Global Healthcare Conference: With clinical validation that has been seen on the target from a large pharma, Contineum has moved its LPA1R antagonist aggressively into the clinic for IPF

Follow BiotechTV

Sponsors

Sponsor Spotlight